Free from Publisher

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

I Lingvay, T Hansen, S Macura, M Marre… - BMJ Open Diabetes …, 2020 - drc.bmj.com
Introduction Gastrointestinal (GI) adverse events (AEs) are the most common AEs with
glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater …
被引用次数：44 相关文章

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

I Lingvay, T Hansen, S Macura, M Marre… - BMJ Open Diabetes …, 2020 - search.proquest.com
Research design and methods Subjects within trials were subdivided into those who
reported (yes/no) nausea/vomiting or any other GI AE. Change from baseline in BW was …

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.

I Lingvay, T Hansen, S Macura, M Marre… - BMJ Open Diabetes …, 2020 - europepmc.org
Research design and methods Subjects within trials were subdivided into those who
reported (yes/no) nausea/vomiting or any other GI AE. Change from baseline in BW was …
[PDF] echealthandwellness.com

[PDF][PDF] Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

I Lingvay, T Hansen, S Macura, M Marre, MA Nauck… - echealthandwellness.com
Introduction Gastrointestinal (GI) adverse events (AEs) are the most common AEs with
glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater …

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

I Lingvay, T Hansen, S Macura… - BMJ open diabetes …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction Gastrointestinal (GI) adverse events (AEs) are the most common AEs with
glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater …
[PDF] yolomedspa.com

[PDF][PDF] Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

I Lingvay, T Hansen, S Macura, M Marre, MA Nauck… - yolomedspa.com
Introduction Gastrointestinal (GI) adverse events (AEs) are the most common AEs with
glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater …
[HTML] nih.gov

[HTML][HTML] Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

I Lingvay, T Hansen, S Macura, M Marre… - BMJ Open Diabetes …, 2020 - ncbi.nlm.nih.gov
Research design and methods Subjects within trials were subdivided into those who
reported (yes/no) nausea/vomiting or any other GI AE. Change from baseline in BW was …

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

I Lingvay, T Hansen, S MacUra… - BMJ Open …, 2020 - utsouthwestern.elsevierpure.com
Introduction Gastrointestinal (GI) adverse events (AEs) are the most common AEs with
glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater …
[PDF] archive.org

[PDF][PDF] Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

I Lingvay, T Hansen, S Macura, M Marre, MA Nauck… - scholar.archive.org
Introduction Gastrointestinal (GI) adverse events (AEs) are the most common AEs with
glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater …

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

I Lingvay, T Hansen, S MacUra, M Marre… - BMJ Open Diabetes …, 2020 - research.regionh.dk
Introduction Gastrointestinal (GI) adverse events (AEs) are the most common AEs with
glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater …